NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming its biggest deficiency – short half life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications

The Company requires additional time to activate clinical sites in certain countries that are participating in its long-term safety trial (trial 012, the “BeyoND” trial) of ND0612> Read More

NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting

Data Presented at 4th World Parkinson Congress > Read More

NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System

The data will be presented at the 4th World Parkinson Congress (WPC) taking place in Portland, Oregon, on September 20-23.> Read More

Our Solutions

NeuroDerm is developing a pipeline of products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients. NeuroDerm is the first to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612L for moderate Parkinson’s disease patients, ND0612H for severe Parkinson’s disease patients and ND0680 for the small subset of severe Parkinson’s disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.